One-Week Inflammatory Kinetics After First-Line Nivolumab Plus Ipilimumab in Metastatic Renal Cell Carcinoma: A Multicenter Landmark Analysis. [PDF]
Inoue T +17 more
europepmc +1 more source
Ipilimumab and nivolumab for cancer treatment: a pharmacovigilance study based on the FDA adverse event reporting system database. [PDF]
Liu R +7 more
europepmc +1 more source
The toxicity profile and temporal dynamics of dual PD-1/CTLA-4 immune checkpoint blockade: a real-world pharmacovigilance study using the FAERS database. [PDF]
Yang Y +5 more
europepmc +1 more source
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma. [PDF]
Kanesvaran R +27 more
europepmc +1 more source
Cardiovascular Immune-Related Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Summary of Case Reports. [PDF]
Godin SL +4 more
europepmc +1 more source
Case Report: Neuroretinitis following combination checkpoint inhibition therapy with nivolumab and ipilimumab for stage IIIC melanoma. [PDF]
Arefin NS, Moon J, Roller AB, Aung MH.
europepmc +1 more source
Severe Multisystem Toxicity from Combination Ipilimumab and Nivolumab in Metastatic Melanoma: A Case Report. [PDF]
Amer B, Manerkar S.
europepmc +1 more source
Optimising cancer immunotherapy and emerging data supporting de-escalation strategies. [PDF]
Hapuarachi B +4 more
europepmc +1 more source
Long-term follow-up from the OMNIVORE trial: response-adaptive nivolumab and ipilimumab in advanced renal cell carcinoma. [PDF]
McKay RR +12 more
europepmc +1 more source

